

Exploring Applications of AI in Genomics and Precision Health

*NASEM BOARD ON HEALTH SCIENCES POLICY
Roundtable on Genomics and Precision Health
Oct 28, 2025*

*Melissa Haendel, PhD, FACMI
University of North Carolina at Chapel Hill
Monarch Initiative*


Slides available at: tislabs.org/NASEM; image credits in speaker notes

Disclosures

Founder of **Alamyra Health**, a genomics diagnostics B-corp dedicated to implementing genomic diagnostics labs in resource or expertise-poor settings.

1/10 americans (400M globally) affected

**each patient's characteristics are akin to the
variation in zebra stripes**




**“When you hear hoof beats,
think horses, not zebras.”**

“There are ~7000 rare diseases”

- per Orphan Drug Act (1983);

**This number is demonstrably
wrong.**

Rare disease: Key to solving numerous bottlenecks in precision medicine



Critical Bottlenecks in Rare Disease Research and Care: A Community Perspective

<https://zenodo.org/records/14906644>

Patient journeys differ across health care systems and d

...for diseases with ICD codes or that are easily phenotyped

Research | [Open Access](#) | Published: 22 October 2021


The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems

Ainslie Tisdale, Christine M. Cutillo, Ramaa Nathan, Pierantonio Russo, Bryan Laraway, Melissa Haendel, Douglas Nowak, Cindy Hasche, Chun-Hung Chan, Emily Griesse, Hugh Dawkins, Oodaye Shukla, David A. Pearce, Joni L. Rutter & Anne R. Pariser [✉](#)


[Orphanet Journal of Rare Diseases](#) 16, Article number: 429 (2021) | [Cite this article](#)

3055 Accesses | 103 Altmetric | [Metrics](#)

bit.ly/ideas-initiative-rd




Rare disease
prevalence
varies across
healthcare
systems &
public sources



Differences in prevalence across healthcare systems are in part due to diagnostics, but also due to differences in coding and billing biases

One problem: what comes out of the EHR is lossy
BUT it is what many AI models are based on



IMOHealth

AI alone can't fix discordant or missing data / know

GENETICS

Mondo: Integrating Disease Terminology Across Communities

Vasilevsky et al October 2025

<https://doi.org/10.1093/genetics/iyaf215>



	Gene Association		Distinct Disease Record				
	ORPHA	OMIM	ORPHA	OMIM	MESH	ICD10	ICD11
Cardiomyopathy, dilated, 1S	52 genes	MYH7					
Cardiomyopathy, hypertrophic, 1		3 genes					
Congenital myopathy 7A, myosin storage, autosomal dominant	MYH7	MYH7					
Congenital myopathy 7B, myosin storage, autosomal recessive	MYH7	MYH7					
Laing distal myopathy	MYH7	MYH7					
Left ventricular noncompaction 5	14 genes	MYH7					
Ebstein malformation of the tricuspid valve	MYH7	0 genes					

LEGEND

-  Absent
-  Present
-  Present but called something else
-  Present but uninterpretable
-  Present but misrepresented; missing genes or mappings
-  Present but grouped or lumped with other term / gene
-  Present based on ORPHA but absent from OMIM or unspecified


AI is already helping us reconcile disparate gene and disease definitions

Many diseases are in only one source

NEW!
>10K!

5 selected
sources

NCIT
DOID
GARD
Orphanet
OMIM



Just 5 sources comprise 10,577 unique rare disease concepts (NOT ~7,000)

Only 333 shared disease concepts in all five sources


Nature Reviews Drug Discovery ([bit.ly/nature-rare-diseases](https://doi.org/10.1093/nrdd/nr025))
Genetics (<https://doi.org/10.1093/genetics/iyaf215>)

Precision Medicine is here, challenges aren't technical

✓ Newborn Screening



✓ Cancer




AI will make it easier/ cheaper;
governance/ policy needed to make implementation reality

Chasm of Approximate Medicine:

Rare diseases, Chronic complex conditions, Mental health conditions,
Autoimmune diseases, Environmental and occupational illnesses, Functional
disorders (eg. IBS, fibromyalgia),
Emerging diseases, Addiction and substance use disorders

Data modalities relevant to health are increasingly highthroughput and must be analyzed in context of their temporal flow.

Low-throughput



High-throughput

Current discourse on AI is lampposting

PATIENT SEEKING CARE

- Patient's experience
- What patient chooses to seek care for
- What the patient has access to care for
- What patient wants to tell provider
- What the patient knows how to tell provider



CARE ENCOUNTER

- What the provider hears
- What the provider chooses to document
- What the EHR makes possible to document
- What the EHR exposes for secondary use
- What the LLM is actually able to do with the note

PERSON-LINKABLE DATA

- Genomics
- Prescriptions
- Surveys
- Wearables
- Vision
- Dental

Approximate
medicine


Structured data, notes,
trial matching

POPULATION-SCALE



- Drug repurposing
- Health economics
- Exposures
- Social determinants
- Public health / disease trends



Good old fashioned AI can improve variant prioritization, leveraging multispecies knowledge



Rare, pathogenic candidate variants



Prioritized genes (and orthologs)



github.com/exomiser
[doi: 10.1038/gim.2015.137](https://doi.org/10.1038/gim.2015.137)

Genomics
england

EXOMISER


hpo

monarch
INITIATIVE

exomiser.readthedocs.io

nejm.org/doi/full/10.1056/NEJMoa2035790

There are many steps in the journey where AI can assist precision medicine and genomics



Takeaways to bridge the chasm of approximate m



Problem: AI models built on data that happens to be available; narrowly applied

Solution: Include more data types, integration, and linkage, and expand applications to more timepoints in the care journey



Problem: AI alone can't fix discordant or missing data / knowledge

Solution: Harden & leverage knowledgebases, deploy socio-technical engineering



Problem: Implementation trails far behind technology.

Solution: Modernize data governance, stewardship, and policies to bring all data to the point of care